Immunitybio IncNASDAQ:IBRX
- LAST PRICE5.0550
- TODAY'S CHANGE (%)-0.0450 (-0.8824%)
- Bid / Lots5.0200/ 22
- Ask / Lots5.0800/ 40
- Open / Previous Close5.0400 / 5.1000
- Day Range
- 52 Week Range
- Volume1,782,059
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBRX |
|---|---|---|
| 09:32 ET | 23197 | 5.0701 |
| 09:33 ET | 11498 | 5.11 |
| 09:35 ET | 7514 | 5.05 |
| 09:37 ET | 7000 | 5.0608 |
| 09:39 ET | 5124 | 5.07 |
| 09:42 ET | 5960 | 5.06 |
| 09:44 ET | 7022 | 5.07 |
| 09:46 ET | 6962 | 5.075 |
| 09:48 ET | 9413 | 5.07 |
| 09:50 ET | 3053 | 5.08 |
| 09:51 ET | 7837 | 5.065 |
| 09:53 ET | 8686 | 5.05 |
| 09:55 ET | 5667 | 5.06 |
| 09:57 ET | 10620 | 5.075 |
| 10:00 ET | 5912 | 5.06 |
| 10:02 ET | 1331 | 5.05 |
| 10:04 ET | 8290 | 5.08 |
| 10:06 ET | 1672 | 5.0989 |
| 10:08 ET | 7928 | 5.11 |
| 10:09 ET | 3528 | 5.1 |
| 10:11 ET | 9374 | 5.115 |
| 10:13 ET | 10104 | 5.155 |
| 10:15 ET | 30642 | 5.13 |
| 10:18 ET | 28079 | 5.09 |
| 10:20 ET | 7596 | 5.085 |
| 10:22 ET | 2672 | 5.09 |
| 10:24 ET | 7342 | 5.0606 |
| 10:26 ET | 9139 | 5.0572 |
| 10:27 ET | 15388 | 5.05 |
| 10:29 ET | 8357 | 5.045 |
| 10:31 ET | 699 | 5.04 |
| 10:33 ET | 12624 | 5.0394 |
| 10:36 ET | 10409 | 5.025 |
| 10:38 ET | 5790 | 5.02 |
| 10:40 ET | 4070 | 5.025 |
| 10:42 ET | 19353 | 5.04 |
| 10:44 ET | 1808 | 5.0435 |
| 10:45 ET | 2300 | 5.045 |
| 10:47 ET | 700 | 5.05 |
| 10:49 ET | 3453 | 5.06 |
| 10:51 ET | 23442 | 5.045 |
| 10:54 ET | 13984 | 5.045 |
| 10:56 ET | 6450 | 5.045 |
| 10:58 ET | 800 | 5.04 |
| 11:00 ET | 23445 | 5.0498 |
| 11:02 ET | 2450 | 5.06 |
| 11:03 ET | 3504 | 5.055 |
| 11:05 ET | 13252 | 5.055 |
| 11:07 ET | 1083 | 5.055 |
| 11:09 ET | 2626 | 5.0501 |
| 11:12 ET | 4560 | 5.065 |
| 11:14 ET | 2275 | 5.0687 |
| 11:16 ET | 2186 | 5.0612 |
| 11:18 ET | 6256 | 5.05 |
| 11:20 ET | 129 | 5.05 |
| 11:21 ET | 2054 | 5.055 |
| 11:23 ET | 2780 | 5.07 |
| 11:25 ET | 9205 | 5.0789 |
| 11:27 ET | 13455 | 5.055 |
| 11:30 ET | 1800 | 5.0513 |
| 11:32 ET | 7739 | 5.0303 |
| 11:34 ET | 7057 | 5.035 |
| 11:36 ET | 4540 | 5.03 |
| 11:38 ET | 10568 | 5.035 |
| 11:39 ET | 3987 | 5.039598 |
| 11:41 ET | 12058 | 5.0682 |
| 11:43 ET | 7601 | 5.075 |
| 11:45 ET | 7859 | 5.0701 |
| 11:48 ET | 1546 | 5.065 |
| 11:50 ET | 4127 | 5.0501 |
| 11:52 ET | 826 | 5.06 |
| 11:54 ET | 2330 | 5.05 |
| 11:56 ET | 5848 | 5.05 |
| 11:57 ET | 3014 | 5.045 |
| 11:59 ET | 2742 | 5.035 |
| 12:01 ET | 1177 | 5.035 |
| 12:03 ET | 35431 | 5.035 |
| 12:06 ET | 3447 | 5.035 |
| 12:08 ET | 1430 | 5.0342 |
| 12:10 ET | 10706 | 5.025 |
| 12:12 ET | 18946 | 5.03 |
| 12:14 ET | 5671 | 5.025 |
| 12:15 ET | 4700 | 5.025 |
| 12:17 ET | 19203 | 5.02 |
| 12:19 ET | 1418 | 5.0199 |
| 12:21 ET | 4920 | 5.02 |
| 12:24 ET | 800 | 5.015 |
| 12:26 ET | 14871 | 5.03 |
| 12:28 ET | 5960 | 5.0254 |
| 12:30 ET | 2888 | 5.025 |
| 12:32 ET | 2600 | 5.025 |
| 12:33 ET | 34595 | 5.055 |
| 12:35 ET | 11332 | 5.065 |
| 12:37 ET | 9362 | 5.0691 |
| 12:39 ET | 696 | 5.065 |
| 12:42 ET | 8614 | 5.065 |
| 12:44 ET | 4072 | 5.065 |
| 12:46 ET | 4084 | 5.075 |
| 12:48 ET | 5359 | 5.075 |
| 12:50 ET | 1032 | 5.075 |
| 12:51 ET | 17049 | 5.075 |
| 12:53 ET | 7553 | 5.0705 |
| 12:55 ET | 55515 | 5.04 |
| 12:57 ET | 30293 | 5.045 |
| 01:00 ET | 734939 | 5.055 |
Nov 21, 2024
DJ ImmunityBio Is Maintained at Buy by D. Boral Capital, from 12:44PM ET on Thursday Nov 21, 2024 by Dow Jones
12:44PM ET on Thursday Nov 21, 2024 by Dow JonesImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment, from 10:00AM ET on Thursday Nov 21, 2024 by Dow Jones
10:00AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 19, 2024
DJ ImmunityBio Is Maintained at Buy by D. Boral Capital, from 12:41PM ET on Tuesday Nov 19, 2024 by Dow Jones
12:41PM ET on Tuesday Nov 19, 2024 by Dow JonesImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements, from 9:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 19, 2024 by Dow JonesImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months, from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immunitybio Inc | 3.6B | -5.8x | --- |
Scholar Rock Holding Corp | 3.5B | -16.9x | --- |
MoonLake Immunotherapeutics | 3.5B | -42.2x | --- |
Xenon Pharmaceuticals Inc | 3.3B | -15.2x | --- |
Verona Pharma PLC | 3.3B | -20.9x | --- |
Agios Pharmaceuticals Inc | 3.4B | 4.8x | --- |
Company Information
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Contact Information
- Headquarters
- 3530 JOHN HOPKINS COURTSAN DIEGO, CA, United States 92121
- Phone
- 858-633-0300
- Fax
- 302-674-5266
Executives
- Executive Chairman of the Board, Global Chief Scientific and Medical Officer
- Patrick Soon-Shiong
- President, Chief Executive Officer
- Richard Adcock
- Chief Financial Officer
- David Sachs
- Chief Corporate Affairs, Director
- Barry Simon
- Lead Independent Director
- Cheryl Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
|---|---|
Revenue (TTM) | $7.3M |
Shares Outstanding | 696.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.87 |
Book Value | $-0.87 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | 486.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,912.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
